Effect of azilsartan versus candesartan on nocturnal blood pressure variation in Japanese patients with essential hypertension

Blood Pressure

Volumn 22, Issue S1, 2013, Pages 22-28

  Rakugi, Hiromi ^a   Kario, Kazuomi ^b   Enya, Kazuaki ^c   Igeta, Masataka ^c   Ikeda, Yoshinori ^c  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Angiotensin receptor blocker; Azilsartan; Candesartan cilexetil; Night time blood pressure; Nocturnal blood pressure variation

Indexed keywords

AZILSARTAN; CANDESARTAN; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; OXADIAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; CIRCADIAN RHYTHM; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; HYPERTENSION; JAPAN; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY;

AGED; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BENZIMIDAZOLES; BLOOD PRESSURE; CIRCADIAN RHYTHM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; JAPAN; MALE; MIDDLE AGED; OXADIAZOLES; TETRAZOLES;

EID: 84883251132     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2013.818758     Document Type: Article

References (29)

1. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease . Circulation. 1989;79:733-743.
2. Kario K. Time for focus on morning hypertension: Pitfall of current antihypertensive medication. Am J Hypertens. 2005;18:149-151.
3. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA. 1999;282:539-546.
4. Metoki H, Ohkubo T, Kikuya M, Asayama K, Obara T, Hashimoto J, et al. Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: The Ohasama study. Hypertension. 2006;47:149-154.
5. Kikuya M, Ohkubo T, Asayama K, Metoki H, Obara T, Saito S, et al. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality:The Ohasama study. Hypertension. 2005;45:240-245.
6. Hoshide S, Kario K, Hoshide Y, Umeda Y, Hashimoto T, Kunii O, et al. Associations between nondipping of nocturnal blood pressure decrease and cardiovascular target organ damage in strictly selected community-dwelling normotensives. Am J Hypertens. 2003;16:434-438.
7. Ohkubo T, Imai Y, Tsuji I, Nagai K, Watanabe N, Minami N, et al. Relation between nocturnal decline in blood pressure and mortality. The Ohasama Study. Am J Hypertens. 1997;10:1201-1207.
8. Kario K, Matsuno T, Kobayashi H, Imiya M, Matsuo M, Shimada K. Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients. Advanced silent cerebrovascular damage in extreme dippers. Hypertension.1996;27:130-135.
9. H. Rakugi et al. 9. Kario K, Pickering TG, Matsuo T, Hoshide S, Schwartz JE, Shimada K. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension 2001; 38:852-857.
10. Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: The Ohasama study. J Hypertens. 2002; 20:2183-2189.
11. Ojima M, Igata H, Tanaka M, Sakamoto H, Kuroita T, Kohara Y, et al. In vitro antagonistic properties of a new angi-otensin type 1 receptor blocker, azilsartan, in receptor binding and function studies . J Pharmacol Exp Ther. 2011;336:801-808.
12. Rakugi H, Enya K, Sugiura K, Ikeda Y. Comparison of the efficacy and safety of azilsartan with that of candesartan cilex-etil in Japanese patients with grade I-II essential hypertension: A randomized, double-blind clinical study. Hypertens Res. 2012;35:552-558.
13. Hermida RC, Ayala DE, Fernandez JR, Calvo C. Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension. Hypertension. 2007;50:715-722.
14. Hermida RC, Ayala DE, Calvo C. Optimal timing for antihy- pertensive dosing: Focus on valsartan. Ther Clin Risk Manag. 2007;3:119-131.
15. Smolensky MH, Hermida RC, Portaluppi F. Comparison of the efficacy of morning versus evening administration of olmesartan in uncomplicated essential hypertension. Chronobiol Int. 2007;24:171-181.
16. Uzu T, Kimura G. Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation. 1999;100:1635-1638.
17. Sherwood A, Steffen PR, Blumenthal JA, Kuhn C, Hinderliter AL. Night-time blood pressure dipping: The role of the sympathetic nervous system. Am J Hypertens. 2002; 15:111-118.
18. Grassi G, Seravalle G, Quarti-Trevano F, Dell'Oro R, Bombelli M, Cuspidi C, et al. Adrenergic, metabolic, and reflex abnormalities in reverse and extreme dipper hypertensives. Hypertension. 2008;52:925-931.
19. Kario K, Schwartz JE, Pickering TG. Changes of nocturnal blood pressure dipping status in hypertensives by night-time dosing of a-adrenergic blocker, doxazosin: Results from the HALT study. Hypertension. 2000;35:787-794.
20. Anan F, Takahashi N, Ooie T, Yufu K, Saikawa T, Yoshimatsu H. Role of insulin resistance in nondipper essential hypertensive patients. Hypertens Res. 2003;26: 669-676.
21. Della Mea P, Lupia M, Bandolin V, Guzzon S, Sonino N, Vettor R, et al. Adiponectin, insulin resistance, and left ventricular structure in dipper and nondipper essential hypertensive patients. Am J Hypertens. 2005;18:30-35.
22. Coltamai L, Maillard M, Simon A, Vogt B, Burnier M. Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans. J Hypertens. 2010;28:520-526.
23. Fukuda M, Yamanaka T, Mizuno M, Motokawa M, Shirasawa Y, Miyagi S, et al. Angiotensin II type 1 receptor blocker, olmesartan, restores nocturnal blood pressure decline by enhancing daytime natriuresis. J Hypertens. 2008;26: 583-588.
24. Fukuda M, Wakamatsu-Yamanaka T, Mizuno M, Miura T, Tomonari T, Kato Y, et al. Angiotensin receptor blockers shift the circadian rhythm of blood pressure by suppressing tubular sodium reabsorption. Am J Physiol Renal Physiol. 2011;301:F953-F957.
25. Kumagai H, Oshima N, Matsuura T, Iigaya K, Imai M, Onimaru H, et al. Importance of rostral ventrolateral medulla neurons in determining efferent sympathetic nerve activity and blood pressure. Hypertens Res. 2012;35:132-141.
26. Anan F, Masaki T, Fukunaga N, Teshima Y, Iwao T, Kaneda K, et al. Pioglitazone shift circadian rhythm of blood pressure from non-dipper to dipper type in type 2 diabetes mellitus. Eur J Clin Invest. 2007;37:709-714.
27. Iwai M, Chen R, Imura Y, Horiuchi M. TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Am J Hypertens. 2007; 20:579-586.
28. Mochizuki Y, Okutani M, Donfeng Y, Iwasaki H, Takusagawa M, Kohno I, et al. Limited reproducibility of circadian variation in blood pressure dippers and nondippers. Am J Hypertens. 1998,11:403-409.
29. Portaluppi F, Smolensky MH. Perspectives on the chrono-therapy of hypertension based on the results of the MAPEC study. Chronobiol Int. 2010;27:1652-1667.